Current state of play for HPV-positive oropharyngeal cancers. (November 2022)

• Record Type: Journal Article
• Authors: Deutsch, Fiona; Regina Bullen, Izabel; Nguyen, Kevin; Tran, Ngoc-Ha; Elliott, Michael; Tran, Nham
• Is Part Of: Cancer treatment reviews. Volume 110(2022)
• Publication Date: 2022-11
• Subjects: HPV-positive oropharyngeal cancers -- De-escalation therapies -- Current diagnosis and treatments; Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2022.102439
• Languages: English
• ISSNs: 0305-7372

Abstract

Highlights: Carcinomas of the oropharynx have increased in incidence with a rise in HPV16 infections. Standard treatment for patients with oropharyngeal cancers does not differ based on HPV status. An adequate de-escalation strategy has yet to be identified. Abstracte: Clinically, HPV-positive oropharyngeal cancers (OPCs) have been shown to have a distinct prognosis, compared to HPV-negative tumours, particularly in survival rates and responses to treatment. These patients have better survival chances and improved prognosis, indicating that a more exhaustive knowledge of these distinctions would aid in the discovery of clinical approaches for both HPV-positive and negative tumours. Furthermore, there is increasing evidence that HPV-related oropharyngeal cancers constitute an epidemiological, molecular, and clinical distinct form as compared to non-HPV related ones therefore, the treatment of these specific subtype of oropharyngeal cancers should adopt a distinct clinical treatment pipeline. Our review will examine the current approaches for the diagnosis and treatment of OPC and discuss the relevance of de-escalation clinical trials in progress.